Gyroscope Capital Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Gyroscope Capital Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$209K	Buy	+600	New	+$210K	0.05%	211

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gyroscope Capital Management Group's VRTX Position: Q3 2023 in Review

Gyroscope Capital Management Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2023: 600 shares worth $209K. The stake represents 0.05% of the portfolio and ranks #211 among its holdings.

1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Gyroscope Capital Management Group held 600 shares of Vertex Pharmaceuticals worth $209K as of Q3 2023.
Vertex Pharmaceuticals was a new Gyroscope Capital Management Group position in Q3 2023.
Vertex Pharmaceuticals made up 0.05% of Gyroscope Capital Management Group's portfolio in Q3 2023, its #211 holding.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Gyroscope Capital Management Group's 13F filing for Q3 2023, filed 13 Nov 2023.